Biohaven Ltd.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Vladimir Coric
- Full Time Employees
- 274
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 215 Church Street New Haven CT United States of America 06510
- IPO Date
- Sep 23, 2022
- CIK
- 0001935979
- Website
- biohaven.com
- Similar Companies
- Business
- Biohaven Ltd. (NYSE: BHVN) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies targeting unmet needs in neuroscience, immunology, and oncology. Founded in 2013 and headquartered in New Haven, Connecticut, the company operates globally with a portfolio spanning multiple proprietary drug development platforms, including Kv7 ion channel modulation, extracellular protein degradation via MoDE and TRAP technologies, TRPM3 antagonism, TYK2/JAK1 inhibition, glutamate modulation, myostatin inhibition, and antibody-drug conjugates. Its lead product candidate, Vyglxia (troriluzole), a tripeptide prodrug of riluzole, targets spinocerebellar ataxias (SCA) and received a Complete Response Letter from the U.S. FDA in November 2025 following submission of its New Drug Application, prompting Biohaven to pursue discussions with the agency and implement portfolio prioritization and cost-optimization measures slashing R&D expenses by approximately 60%. Core pipeline assets include taldefgrobep, a myostatin inhibitor in development for spinal muscular atrophy and obesity; BHV-7000, a selective Kv7.2/7.3 activator for epilepsy, major depressive disorder, and bipolar depression; BHV-2100, a TRPM3 antagonist for pain disorders; BHV-8000, a brain-penetrant TYK2/JAK1 inhibitor for Parkinson's disease, Alzheimer's disease, multiple sclerosis, and prevention of amyloid-related imaging abnormalities; BHV-1300 and BHV-1310, IgG degraders for rheumatoid arthritis, Graves' disease, and myasthenia gravis; BHV-1400, a Gd-IgA1 degrader for IgA nephropathy; BHV-1600, a β1AR autoantibody degrader for peripartum cardiomyopathy; and oncology candidates such as BHV-1510 (Trop2 ADC), BHV-1530 (FGFR3 ADC), and BHV-1500 (CD30 ADC), alongside undisclosed targets from collaborations with Merus and GeneQuantum. Recent developments encompass a non-dilutive financing agreement with Oberland Capital Management in April 2025 providing up to $600 million in senior secured notes to support pipeline advancement and potential launches; an upsized public offering of common shares in November 2025 generating approximately $200 million in gross proceeds; first-in-human dosing with BHV-1400 demonstrating rapid Gd-IgA1 lowering in IgA nephropathy; and ongoing advancement of preclinical antibody-drug conjugates. Biohaven, which emerged from the 2022 spin-off and divestiture of its migraine portfolio (including Nurtec ODT and Zavzpret) to Pfizer, targets patients with rare genetic disorders, neurodegenerative conditions, autoimmune diseases, chronic pain, metabolic disorders, and cancers across the United States and international markets.
Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload
Biohaven: Nice Pipeline Momentum, But Its Runway Is A Risk
Biohaven Announces Scientific Leadership Transitions
Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator
Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study Initiations
Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
Biohaven: Despite Today's Gains, I Remain Skeptical
Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy
Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile
Biohaven Ltd. (BHVN) Upgraded to Buy: Here's Why
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results
Biohaven: Downgrade To Hold On Troriluzole Setback And Obesity Data 2nd Half 2026
Why Biohaven Stock Crushed it on Monday
Aberdeen Group plc Buys Shares of 693,452 Biohaven Ltd. $BHVN
SG Americas Securities LLC Grows Holdings in Biohaven Ltd. $BHVN
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential
Biohaven Ltd. (NYSE:BHVN) Given Average Recommendation of “Moderate Buy” by Brokerages